Lupus News and Research

Latest Lupus News and Research

AARDA launches campaign on family AQ

In honor of the designation of March as National Autoimmune Disease Awareness Month by the U.S. Senate on March 4, 2010, the American Autoimmune Related Diseases Association (AARDA) wants to help you learn your family's AQ. AQ is a play on IQ that stands for Autoimmune Quotient. It's about knowing how likely you or a loved one is to develop an autoimmune disease, based on the prevalence of these diseases and your family history. The campaign features AARDA National Spokesperson and Actress Kellie Martin, best known for her memorable roles on "E.R." and "Life Goes On."

22 Mar 2010

Survey unveils impact of gene regulation on human health

Researchers are only beginning to understand how individual variation in gene regulation can have a lasting impact on one's health and susceptibility to certain diseases. Now, an ambitious survey of the human genome has identified differences in the binding of master regulators called transcription factors to DNA that affect how genes are expressed in different people.

19 Mar 2010

Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC

Human Genome Sciences, Inc. today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).

17 Mar 2010

Human Genome Sciences to deploy Aegis Analytical's Discoverant manufacturing intelligence solution

Aegis Analytical Corp., the leading provider of Enterprise Manufacturing Intelligence software, announced today that Human Genome Sciences, Inc. will deploy Aegis’ Discoverant® as its data management, analytics and reporting solution in the scale-up and production of BENLYSTA™ (belimumab), an investigational drug for the treatment of systemic lupus that has successfully completed Phase 3 trials.

17 Mar 2010

Liquid CMO seeks osteoarthritis and fibromyalgia patients for pilot study in Phoenix

Makers of a new liquid natural supplement formulation of Cetyl-Myristoleate (CMO) are seeking osteoarthritis and fibromyalgia patients for a pilot study in Phoenix beginning Monday, April 12, 2010.

16 Mar 2010

Cephalon Australia granted exclusive license to develop Innate Immune's antibodies for treatment of asthma, SLE

Innate Immune, Inc., a privately held biotechnology company, today announced that it has granted to Cephalon Australia Pty Ltd an exclusive license to patents for the development of its antibodies for the treatment of asthma and systemic lupus erythematosis (SLE).

15 Mar 2010

New findings may help develop potential therapies for lupus, rheumatoid arthritis and cancer

Medical Research Council (MRC) scientists at the University of Leicester have made a new advance in understanding how the body fights certain types of cancer and other disease such as Lupus and rheumatoid arthritis.

15 Mar 2010

Study shows experimental thyroid drug reduces cholesterol

An experimental thyroid drug reduces cholesterol without the troublesome side effects experienced by some people on statins, according to a study published today in The New England Journal of Medicine. An international team of investigators at Johns Hopkins Medical Institutions, the Karolinska University Hospital and Institute, and The Feinstein Institute for Medical Research tested a substance called Eprotirome in patients with high cholesterol.

12 Mar 2010

BioInvent International, HGS announce collaboration to develop therapeutic monoclonal antibodies

BioInvent International AB and Human Genome Sciences, Inc. today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies which specifically target antigens discovered by HGS.

11 Mar 2010

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

Human Genome Sciences, Inc. and BioInvent International AB today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by HGS.

11 Mar 2010

March designated as 'National Autoimmune Diseases Awareness Month'

On the evening of March 4, 2010, the U.S. Senate passed a resolution designating March as "National Autoimmune Diseases Awareness Month" and supporting efforts to increase awareness of autoimmune diseases and increase funding for autoimmune disease research. The Senate resolution (S.RES.372) was introduced by Michigan Senator Carl Levin on December 8, 2009.

9 Mar 2010

Gaps in lupus research and understanding have profound effect on people living with disease

On March 16, 2010, an anticipated 1,000 advocates will band together for lupus in person and virtually by phone, email, and through social media networks, to share their personal stories with Members of Congress during the Lupus Foundation of America’s Twelfth Annual Advocacy Day.

9 Mar 2010

Anthera Pharmaceuticals' 6.0M common stock public offering: Merriman Curhan Ford acts as co-manager

Merriman Curhan Ford Group, Inc. was a co-manager in Anthera Pharmaceuticals, Inc.'s public offering of 6.0 million shares of common stock.

6 Mar 2010

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010.

5 Mar 2010

Anthera Pharmaceuticals completes initial public offering at $7.00 per share

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the completion of its initial public offering of six million shares of common stock at a price of $7.00 per share. The net proceeds of the offering to Anthera, after deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, were approximately $36.7 million.

5 Mar 2010

Dermatologist speaks about common forms of hair loss and treatment options at 68th Annual Meeting

For many women, unexplained hair loss can take a significant psychological toll on their overall quality of life. From altering their hairstyle to hide a thinning part to scaling back their hair care regimen in an effort to halt further hair loss, women try countless ways to cover up this problem - and the results are often lukewarm at best.

4 Mar 2010

AARDA report examining current state of AD released at the National Autoimmune Diseases Summit

A groundbreaking new report from the American Autoimmune Related Diseases Association, examining the current state of autoimmune disease (AD) and its economic and social impact globally and in the U.S., was released today at the National Autoimmune Diseases Summit: The Global State of Autoimmunity Today, held to kick-off National Autoimmune Disease Awareness Month.

4 Mar 2010

CBT effective in treating patients suffering from lupus and high levels of daily stress

This study shows that cognitive behavioural therapy (CBT) is effective in dealing with patients suffering from lupus and high levels of daily stress as it significantly reduces the incidence of psychological disorders associated with lupus and improves and maintains patients' QOL, despite there being no significant reduction in the disease activity index.

3 Mar 2010

Corgenix Medical announces the availability of new automation friendly anti-phospholipid assay format

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has announced the availability of its new automation friendly anti-phospholipid assay format.

2 Mar 2010

Increase in anti-Apo A-I, anti-HDL and anti-CRP may lead to atherosclerosis in SLE patients

A study by researchers in Australia and the United Kingdom suggests that autoantibodies to fat binding proteins significantly increase in systemic lupus erythematosus (SLE) patients with active disease. This increase in anti-apolipoprotein (anti-Apo A-I), anti-high-density lipoprotein (anti-HDL), and anti-C-reactive protein (anti-CRP) may contribute to the development of atherosclerosis in SLE patients, placing them at risk for cardiovascular disease (CVD).

25 Feb 2010

Lupus News and Research

Latest Lupus News and Research

AARDA launches campaign on family AQ

Survey unveils impact of gene regulation on human health

Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC

Human Genome Sciences to deploy Aegis Analytical's Discoverant manufacturing intelligence solution

Liquid CMO seeks osteoarthritis and fibromyalgia patients for pilot study in Phoenix

Cephalon Australia granted exclusive license to develop Innate Immune's antibodies for treatment of asthma, SLE

New findings may help develop potential therapies for lupus, rheumatoid arthritis and cancer

Study shows experimental thyroid drug reduces cholesterol

BioInvent International, HGS announce collaboration to develop therapeutic monoclonal antibodies

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

March designated as 'National Autoimmune Diseases Awareness Month'

Gaps in lupus research and understanding have profound effect on people living with disease

Anthera Pharmaceuticals' 6.0M common stock public offering: Merriman Curhan Ford acts as co-manager

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Anthera Pharmaceuticals completes initial public offering at $7.00 per share

Dermatologist speaks about common forms of hair loss and treatment options at 68th Annual Meeting

AARDA report examining current state of AD released at the National Autoimmune Diseases Summit

CBT effective in treating patients suffering from lupus and high levels of daily stress

Corgenix Medical announces the availability of new automation friendly anti-phospholipid assay format

Increase in anti-Apo A-I, anti-HDL and anti-CRP may lead to atherosclerosis in SLE patients

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Lupus News and Research

Latest Lupus News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in